OSI maintained by Merrill at buy

OSI Pharmaceuticals was maintained by Merrill Lynch analyst Eric Ende at a buy rating on news that the first-year efficacy data comparing Lucentis to Visudyne in patients with age-related macular degeneration showed excellent efficacy. Shares of the Melville, N.Y., biotechnology company were up 42 cents, or 1.55%, at $27.49 on volume of 1,152,574 shares versus the three-month running average of 1,772,720 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.